NCT06423326 2026-04-22
Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer
Emory University
Phase 2 Recruiting
Clinical Trials
21 trialsNCT05687123 2026-04-21
Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT04172532 2026-04-13
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
National Cancer Institute (NCI)
Phase 1/2 Recruiting
NCT04550494 2026-04-13
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05411094 2026-04-13
Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT06454383 2026-04-13
Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer
City of Hope Medical Center
Phase 1 Recruiting
NCT06958328 2026-04-08
LAP100
NRG Oncology
Phase 3 Recruiting
NCT05961982 2026-03-23
ERASE
Ohio State University Comprehensive Cancer Center
Phase NA Recruiting
NCT07089940 2026-03-23
OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
OHSU Knight Cancer Institute
Phase EARLY_PHASE1 Recruiting
NCT06906562 2026-02-17
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT07214298 2026-02-06
Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
Roswell Park Cancer Institute
Phase 1/2 Recruiting
NCT06381154 2026-01-30
Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer
Mayo Clinic
Phase 2 Recruiting
NCT06073431 2026-01-09
LOTUS
University of Rochester
Recruiting
NCT07226856 2025-12-22
BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma
Mayo Clinic
Phase 2 Recruiting
NCT04858009 2025-12-16
Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis
Mayo Clinic
Phase 2 Recruiting
NCT05518903 2025-10-02
Investigational Scan (68Ga-FAPI-46 PET/CT) for Imaging of Cancer-Associated Fibroblasts for Localized Pancreatic Ductal Adenocarcinoma
Mayo Clinic
Phase 2 Recruiting
NCT07118176 2025-08-12
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Jonsson Comprehensive Cancer Center
Phase 1 Recruiting
NCT06549725 2025-08-01
Clinical Performance of Medical Device Software "Lipidica 1.0" for Processing Data Generated by Lipidomic Analysis in Pancreatic Cancer Screening
Lipidica, a.s.
Phase NA Recruiting
NCT06122896 2025-06-03
Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
Dana-Farber Cancer Institute
Phase EARLY_PHASE1 Recruiting
NCT05058846 2025-05-02
Pilot Study of Pancreatic Cancer Screening
University of California, San Francisco
Recruiting
NCT05733000 2023-03-10
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
Northwestern University
Phase 2 Recruiting